Articles, Cellular/Molecular
AZ-4217: A High Potency BACE Inhibitor Displaying Acute Central Efficacy in Different In Vivo Models and Reduced Amyloid Deposition in Tg2576 Mice
Susanna Eketjäll, Juliette Janson, Fredrik Jeppsson, Alexander Svanhagen, Karin Kolmodin, Susanne Gustavsson, Ann-Cathrin Radesäter, Kristina Eliason, Sveinn Briem, Paulina Appelkvist, Camilla Niva, Anna-Lena Berg, Sofia Karlström, Britt-Marie Swahn and Johanna Fälting
Journal of Neuroscience 12 June 2013, 33 (24) 10075-10084; DOI: https://doi.org/10.1523/JNEUROSCI.1165-13.2013
Susanna Eketjäll
1Innovative Medicines AstraZeneca, CNS & Pain, S-151 85 Södertälje, Sweden and
2AstraZeneca Translational Sciences Centre, Science for Life Laboratory, S-171 65 Solna, Sweden
Juliette Janson
1Innovative Medicines AstraZeneca, CNS & Pain, S-151 85 Södertälje, Sweden and
Fredrik Jeppsson
1Innovative Medicines AstraZeneca, CNS & Pain, S-151 85 Södertälje, Sweden and
Alexander Svanhagen
1Innovative Medicines AstraZeneca, CNS & Pain, S-151 85 Södertälje, Sweden and
Karin Kolmodin
1Innovative Medicines AstraZeneca, CNS & Pain, S-151 85 Södertälje, Sweden and
Susanne Gustavsson
1Innovative Medicines AstraZeneca, CNS & Pain, S-151 85 Södertälje, Sweden and
Ann-Cathrin Radesäter
1Innovative Medicines AstraZeneca, CNS & Pain, S-151 85 Södertälje, Sweden and
Kristina Eliason
1Innovative Medicines AstraZeneca, CNS & Pain, S-151 85 Södertälje, Sweden and
Sveinn Briem
1Innovative Medicines AstraZeneca, CNS & Pain, S-151 85 Södertälje, Sweden and
Paulina Appelkvist
1Innovative Medicines AstraZeneca, CNS & Pain, S-151 85 Södertälje, Sweden and
Camilla Niva
1Innovative Medicines AstraZeneca, CNS & Pain, S-151 85 Södertälje, Sweden and
Anna-Lena Berg
1Innovative Medicines AstraZeneca, CNS & Pain, S-151 85 Södertälje, Sweden and
Sofia Karlström
1Innovative Medicines AstraZeneca, CNS & Pain, S-151 85 Södertälje, Sweden and
Britt-Marie Swahn
1Innovative Medicines AstraZeneca, CNS & Pain, S-151 85 Södertälje, Sweden and
Johanna Fälting
1Innovative Medicines AstraZeneca, CNS & Pain, S-151 85 Södertälje, Sweden and

Published eLetters
Guidelines
As a forum for professional feedback, submissions of letters are open to all. You do not need to be a subscriber. To avoid redundancy, we urge you to read other people's letters before submitting your own. Name, current appointment, place of work, and email address are required to send a letter, and will be published with your review. We also require that you declare any competing financial interests. Unprofessional submissions will not be considered or responded to.
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Journal of Neuroscience
Vol. 33, Issue 24
12 Jun 2013
AZ-4217: A High Potency BACE Inhibitor Displaying Acute Central Efficacy in Different In Vivo Models and Reduced Amyloid Deposition in Tg2576 Mice
Susanna Eketjäll, Juliette Janson, Fredrik Jeppsson, Alexander Svanhagen, Karin Kolmodin, Susanne Gustavsson, Ann-Cathrin Radesäter, Kristina Eliason, Sveinn Briem, Paulina Appelkvist, Camilla Niva, Anna-Lena Berg, Sofia Karlström, Britt-Marie Swahn, Johanna Fälting
Journal of Neuroscience 12 June 2013, 33 (24) 10075-10084; DOI: 10.1523/JNEUROSCI.1165-13.2013
AZ-4217: A High Potency BACE Inhibitor Displaying Acute Central Efficacy in Different In Vivo Models and Reduced Amyloid Deposition in Tg2576 Mice
Susanna Eketjäll, Juliette Janson, Fredrik Jeppsson, Alexander Svanhagen, Karin Kolmodin, Susanne Gustavsson, Ann-Cathrin Radesäter, Kristina Eliason, Sveinn Briem, Paulina Appelkvist, Camilla Niva, Anna-Lena Berg, Sofia Karlström, Britt-Marie Swahn, Johanna Fälting
Journal of Neuroscience 12 June 2013, 33 (24) 10075-10084; DOI: 10.1523/JNEUROSCI.1165-13.2013
Jump to section
Responses to this article
Jump to comment:
No eLetters have been published for this article.